Lyfetec, Inc. (Formerly Tri-Star Holdings, Inc.) in Negotiations With Chinese Medical Manufacturer for Global Distribution Rights

FT. LAUDERDALE, FL--(Marketwire - April 16, 2009) - LYFETEC, Inc. (PINKSHEETS: TSHL) has been negotiating with an as-of-yet undisclosed biotech company for the distribution and manufacturing rights to over 150 different types of home medical test kits designed and produced by this high tech bio chemical Chinese manufacturer. LYFETEC, Inc. plans to be the licensed global wholesale distributor of the products to dealers serving the consumer and private medical practice market sectors worldwide. LyfeTec, Inc. has already generated the interest of parties for significant orders from retail distributors in several individual markets. Upon the execution of the definitive agreements, and customary closing arrangements, company management will release the details of the deal as well as of expected and closed contracts. Management noted that the arrangement should generate significant annual revenues for the Company with strong net profits, and that the completion of these initial transactions will mark the beginning of a campaign which will lead to the worldwide availability of LyfeTec products and services.

Mr. Steven Cohen, LyfeTec Executive Vice President, said, “We are establishing a new approach in the medical industry for consumers to be able to save money -- especially in these hard times -- by offering test kits directly to doctors and retail consumers affordably. In addition, health insurers and long-term care providers can increase efficiency and cut the costs of in-patient service provision by monitoring their patient’s care remotely.”

Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.